Target intelligence / Profile preview

APC membrane recruitment protein 1 (AMER1)

Target
AMER1
Molecular classification
Scaffold protein, Other (adaptor/membrane recruitment protein), Tumor suppressor
01

Overview

APC membrane recruitment protein 1 (AMER1, also known as WTX or FAM123B) is a multifunctional scaffold protein that plays a key role as a tumor suppressor and negative regulator of the canonical Wnt/β‐catenin signaling pathway. AMER1 binds directly to APC (adenomatous polyposis coli), Axin, and β-catenin, orchestrating the assembly of the β‐catenin destruction complex at the plasma membrane, which leads to β-catenin ubiquitination and degradation. It acts via distinct membrane-binding domains and contains multiple APC interaction motifs (A1-A4), which are crucial for its recruitment and regulatory functions. Mutations in AMER1 underlie the developmental disorder osteopathia striata with cranial sclerosis (OSCS) and predispose to certain cancers, including Wilms tumor. In some cellular contexts, AMER1 can also act as a positive regulator of Wnt signaling, for example by promoting LRP6 phosphorylation. The protein is essential for normal kidney and bone development, and its tumor suppressive activity is context- and localization-dependent.

Other names
AMER1WTXFAM123BWilms tumor gene on the X chromosome proteinosteopathia striata with cranial sclerosis proteinOSCSfamily with sequence similarity 123BRP11-403E24.2FLJ39827protein FAM123Badenomatous polyposis coli membrane recruitment 1
02

Mechanism of action

Scaffold assembly promoting β-catenin ubiquitination and degradation; Inhibition of Wnt/β-catenin signaling by recruiting destruction complex to plasma membrane; Promotion of LRP6 phosphorylation (context-dependent upregulation of Wnt signaling)

03

Biological functions

Regulation of Wnt/β‐catenin signalingScaffold assembly for β‐catenin destruction complexNegative and context-dependent positive regulation of Wnt pathwayMembrane recruitment of APC and AxinCell adhesion and migrationTranscriptional co-activation (Wilms tumor protein WT1)Regulation of cell proliferation and differentiation
04

Disease associations

Cancer (Wilms tumor, colorectal cancer, other solid tumors)Congenital bone disorders (Osteopathia striata with cranial sclerosis)Other developmental syndromes
05

Safety considerations

Germline mutations cause serious developmental defects (e.g., OSCS, cranial sclerosis)Somatic mutations linked to tumorigenesisCritical tumor suppressor, so inhibition poses oncogenic risk
06

Biomarkers

AMER1 mutation or loss (for OSCS and Wilms tumor diagnosis/prognosis)β-catenin levels (indirect, via pathway activity)

Beyond the preview

Go deeper on APC membrane recruitment protein 1 (AMER1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on APC membrane recruitment protein 1 (AMER1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call